Literature DB >> 21060940

Bivalent inhibitors of the tyrosine kinases ABL and SRC: determinants of potency and selectivity.

Zachary B Hill1, B Gayani K Perera, Dustin J Maly.   

Abstract

We recently reported a chemical genetic method for generating bivalent inhibitors of protein kinases. This method relies on the use of the DNA repair enzyme O(6)-alkylguanine-DNA alkyltransferase (AGT) to display an ATP-competitive inhibitor and a ligand that targets a secondary binding domain. With this method potent and selective inhibitors of the tyrosine kinases SRC and ABL were identified. Here, we dissect the molecular determinants of the potency and selectivity of these bivalent ligands. Systematic analysis of ATP-competitive inhibitors with varying linker lengths revealed that SRC and ABL have differential sensitivities to ligand presentation. Generation of bivalent constructs that contain ligands with differential affinities for the ATP-binding sites and SH3 domains of SRC and ABL demonstrated the modular nature of inhibitors based on the AGT scaffold. Furthermore, these studies revealed that the interaction between the SH3 domain ligand and the kinase SH3 domain is the major selectivity determinant amongst closely-related tyrosine kinases. Finally, the potency of bivalent inhibitors against distinct phospho-isoforms of SRC was determined. Overall, these results provide insight into how individual ligands can be modified to provide more potent and selective bivalent inhibitors of protein kinases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21060940      PMCID: PMC3268058          DOI: 10.1039/c0mb00108b

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  33 in total

Review 1.  Signaling--2000 and beyond.

Authors:  T Hunter
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Molecular rulers: an assessment of distance and spatial relationships of Src tyrosine kinase Sh2 and active site regions.

Authors:  A A Profit; T R Lee; J Niu; D S Lawrence
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

3.  Synthesis and applications of chemical probes for human O6-alkylguanine-DNA alkyltransferase.

Authors:  R Damoiseaux; A Keppler; K Johnsson
Journal:  Chembiochem       Date:  2001-04-02       Impact factor: 3.164

Review 4.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

5.  A general method for the covalent labeling of fusion proteins with small molecules in vivo.

Authors:  Antje Keppler; Susanne Gendreizig; Thomas Gronemeyer; Horst Pick; Horst Vogel; Kai Johnsson
Journal:  Nat Biotechnol       Date:  2002-12-09       Impact factor: 54.908

Review 6.  Oncogenic kinase signalling.

Authors:  P Blume-Jensen; T Hunter
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

Review 7.  Designing bisubstrate analog inhibitors for protein kinases.

Authors:  Keykavous Parang; Philip A Cole
Journal:  Pharmacol Ther       Date:  2002 Feb-Mar       Impact factor: 12.310

Review 8.  Protein kinases--the major drug targets of the twenty-first century?

Authors:  Philip Cohen
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

9.  Affinity reagents that target a specific inactive form of protein kinases.

Authors:  Pratistha Ranjitkar; Amanda M Brock; Dustin J Maly
Journal:  Chem Biol       Date:  2010-02-26

10.  Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.

Authors:  A J Barker; K H Gibson; W Grundy; A A Godfrey; J J Barlow; M P Healy; J R Woodburn; S E Ashton; B J Curry; L Scarlett; L Henthorn; L Richards
Journal:  Bioorg Med Chem Lett       Date:  2001-07-23       Impact factor: 2.823

View more
  5 in total

1.  Targeting diverse signaling interaction sites allows the rapid generation of bivalent kinase inhibitors.

Authors:  Zachary B Hill; B Gayani K Perera; Simeon S Andrews; Dustin J Maly
Journal:  ACS Chem Biol       Date:  2011-12-22       Impact factor: 5.100

Review 2.  Bivalent inhibitors of protein kinases.

Authors:  Carrie M Gower; Matthew E K Chang; Dustin J Maly
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-02-25       Impact factor: 8.250

3.  Conversion of a Single Polypharmacological Agent into Selective Bivalent Inhibitors of Intracellular Kinase Activity.

Authors:  Carrie M Gower; Jason R Thomas; Edmund Harrington; Jason Murphy; Matthew E K Chang; Ivan Cornella-Taracido; Rishi K Jain; Markus Schirle; Dustin J Maly
Journal:  ACS Chem Biol       Date:  2015-11-06       Impact factor: 5.100

4.  Potent and selective inhibition of SH3 domains with dirhodium metalloinhibitors.

Authors:  Farrukh Vohidov; Sarah E Knudsen; Paul G Leonard; Jun Ohata; Michael J Wheadon; Brian V Popp; John E Ladbury; Zachary T Ball
Journal:  Chem Sci       Date:  2015-06-03       Impact factor: 9.825

5.  Examining the influence of specificity ligands and ATP-competitive ligands on the overall effectiveness of bivalent kinase inhibitors.

Authors:  Margaret L Wong; Jason Murphy; Edmund Harrington; Carrie M Gower; Rishi K Jain; Markus Schirle; Jason R Thomas
Journal:  Proteome Sci       Date:  2017-07-17       Impact factor: 2.480

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.